134419-46-8Relevant academic research and scientific papers
EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS
-
Page/Page column 55, (2009/06/27)
The present invention is related to novel compounds of formula (I) having equilibrative nucleoside transporter ENTl inhibiting properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment of diseases linked to the inhibition of ENTl receptors in animals, in particular humans.
Urea thiadiazole inhibitors of plasminogen activator inhibior-1
-
Page/Page column 35, (2010/02/11)
Methods of treating disorders associated with elevated levels of PAI-1 are disclosed comprising administering to a patient in need thereof a therapeutically effective amount of at least one compound of formula (I), or a pharmaceutically-acceptable salt, prodrug, stereoisomer or solvate thereof, wherein: A is aryl o heteroaryl, and R1-R12, are defined herein. The invention also pertains to pharmaceutical compositions and compounds within the scope of formula (I) as well as medicaments and articles of manufacture comprising compounds of formula (I).
Substituted benzamides and radioligand analogs and methods of use
-
, (2008/06/13)
This invention provides compounds of the formula I STR1 wherein, R1, R2, and R3 are independently ?a first halogen atom,! fluorine, chlorine, bromine, iodine, alkyl, alkenyl, alkynyl, alkoxy, alkenoxy, or alkynoxy, wherein R2 and R3 can also independently be H, wherein at least one of R1, R2, and R3 is ?a second halogen atom! fluorine, bromine, iodine or is substituted with ?a second halogen atom,! fluorine, bromine or iodine and R4 is H or lower alkyl. The invention also provides precursors of formula I, radioactive analogs of formula I, and methods of using the compounds for the identification of 5-HT-3 receptors and the detection and treatment of abnormal conditions associated therewith.
